Skip to main content



17-12-2021 | Diabetes | News | Article

Metformin, but not sulfonylurea, may reduce poor outcome risk post HHF

Initiating metformin following hospitalization for heart failure may reduce the risk for death or further HHF in older people with comorbid diabetes, but only if they have a preserved ejection fraction, study findings indicate.

10-12-2021 | Diabetes | News | Article

Study highlights importance of diabetes for obesity-related HF risk

Higher BMI, waist circumference, and fat mass are each significantly associated with an increased risk for heart failure among older people with diabetes but not among those without diabetes, US researchers report.

30-11-2021 | Oncology | News | Article

Metformin, statins may help prevent advanced prostate cancer deaths

Postdiagnostic metformin or statin use may reduce the risk for death among people with advanced prostate cancer, suggests an analysis of US Veteran Health Administration data.

22-11-2021 | Diabetes | News | Article

CVD risk factors vary by HbA1c trajectory

Risk factors for cardiovascular disease may vary by longitudinal glycated hemoglobin trajectory in people with type 1 diabetes, US researchers report.

27-10-2021 | Diabetes | News | Article

Cardiovascular risk greatest among people with prediabetes

People with glycated hemoglobin levels just below the diabetes diagnosis threshold have the greatest risk for major adverse cardiovascular events and death, suggests a study of individuals in the upper normal glycemic range.

26-10-2021 | Oncology | News | Article

ICIs linked to increased venous thromboembolism risk

A large single-center study has found an association between immune checkpoint inhibitor use and an increased incidence of venous thromboembolism in people with cancer.

26-10-2021 | Diabetes | News | Article

Statin treatment linked to increased likelihood of diabetes progression

Study findings published in JAMA Internal Medicine show that treatment initiation with statins is associated with an elevated risk for diabetes progression.

18-10-2021 | Rheumatology | News | Article

Diastolic dysfunction elevated in premenopausal women with RA

Premenopausal women with rheumatoid arthritis are twice as likely as their healthy counterparts to have subclinical diastolic dysfunction, Korean study findings indicate.

01-10-2021 | Diabetes | News | Article

Higher risk for incident CV, renal disease with type 1 vs type 2 diabetes

People with type 1 diabetes have a greater risk for incident cardiovascular and renal disease than those with type 2 diabetes, suggest findings from a French nationwide observational study presented at the virtual 57th EASD Annual Meeting.

01-09-2021 | Diabetes | News | Article

Telmisartan linked to reduced dementia risk in people with type 2 diabetes, hypertension

Study results suggest that telmisartan use in people with concomitant type 2 diabetes and hypertension is associated with a lower incidence of dementia and ischemic stroke compared with the use of other angiotensin receptor blockers.

29-08-2021 | Diabetes | News | Article

Empagliflozin has broad beneficial effect on HFpEF outcomes

Empagliflozin treatment produces significant reductions in the risk for a broad range of inpatient and outpatient heart failure outcomes in people with a preserved ejection fraction, shows further analysis of EMPEROR-Preserved.

29-08-2021 | Diabetes | News | Article

HF and CKD doubly dangerous for people with type 2 diabetes

Rates of hospitalization and mortality are increased in people with type 2 diabetes who also have heart failure or chronic kidney disease, and more so if they have both conditions, say researchers.

28-08-2021 | Diabetes | News | Article

FIGARO-DKD: Finerenone cardioprotective across broad range of renal risk

Finerenone protects against adverse cardiovascular outcomes in people with type 2 diabetes and mild or moderate chronic kidney disease, the FIGARO-DKD investigators have reported at the virtual ESC Congress 2021.

27-08-2021 | Diabetes | News | Article

EMPEROR-Preserved: A win for empagliflozin in HFpEF

Empagliflozin has become the first medication to demonstrate a clear protective effect in people with heart failure and preserved ejection fraction, report the EMPEROR-Preserved investigators.

27-08-2021 | Diabetes | News | Article

Dapagliflozin benefits wide range of people with CKD

Dapagliflozin reduces the risk for kidney failure, heart failure hospitalization, and death in people with chronic kidney disease, irrespective of their history of HF, DAPA-CKD study data show.

26-07-2021 | Rheumatology | News | Article

Observational data stress CV benefits of glucocorticoid tapering in RA

Steroid-naive patients with rheumatoid arthritis have a dose- and duration-dependent increased risk for cardiovascular events following glucocorticoid initiation, real-world study data show.

18-06-2021 | Diabetes | News | Article

Early polyneuropathy may be a risk factor for CVD

People with symptoms indicative of diabetic polyneuropathy near the time of type 2 diabetes diagnosis have a “markedly higher” risk for subsequent cardiovascular disease than those without, researchers report.

28-04-2021 | Oncology | News | Article

AHA issues statement on managing hormonal therapy-related CVD risks

The American Heart Association has released a consensus statement on the management of cardiovascular disease in patients receiving hormonal therapies for breast or prostate cancer.

28-04-2021 | Oncology | News | Article

Cardiovascular AEs of prostate cancer hormone therapies reported

An analysis of the FDA Adverse Event Reporting System has provided detailed insight into cardiovascular adverse events associated with different classes of androgen deprivation therapies.

22-04-2021 | Oncology | News | Article

Limited evidence to link antihypertensive use to cancer

An extensive meta-analysis of individual participant data has not found consistent evidence to indicate that antihypertensive use is associated with an increased risk for cancer.

Image Credits